Browsing Tag
MEK inhibitor
1 post
Pasithea Therapeutics raises $60m in discounted public offering as biotech funding momentum returns
Find out how Pasithea Therapeutics’ $60 million stock offering reshapes its clinical runway, dilution outlook, and investor sentiment.